Selinexor in relapsed/refractory multiple myeloma

Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies, patients ultimately relapse. Sel...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Joshua, Madduri, Deepu, Richard, Shambavi, Chari, Ajai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Advances in Multiple Myeloma (MM)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285937/
https://www.ncbi.nlm.nih.gov/pubmed/32566115
http://dx.doi.org/10.1177/2040620720930629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285937/
https://www.ncbi.nlm.nih.gov/pubmed/32566115
http://dx.doi.org/10.1177/2040620720930629

Ejemplares similares